Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Share News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Redx Surges On Potential Takeover Offer

Tue, 31st Dec 2019 10:34

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.

----------

FTSE 100 - LOSERS

----------

HSBC, down 0.6%. The bank is planning to expand its exchange traded fund range in 2020 in order to revitalise its underperforming asset management business, the Financial Times reported. Nicholas Moreau, who was appointed chief executive of HSBC's asset management division in August, has devised a series of initiatives aimed at reinvigorating growth at a time when the London-listed bank is aggressively cutting costs, the FT said. In the first half of 2020, HSBC will launch eight ETF's employing environmental, social and governance metrics to tap into rising investor demand for ESG-focused strategies. HSBC also plans to develop a fixed income ETF platform in 2020 and to launch a range of precious metals tracker funds later in the year, the FT noted.

----------

FTSE 250 - WINNERS

----------

CLS Holdings, up 0.8%. The company said it will sell a portfolio of 19 regional offices in the UK for GBP65.0 million to Capital Partners, a Singaporean investment firm. The offices are located across the UK outside of the South East. Therefore the sale is in line with the FTSE 250-listed company's strategy of actively recycling its capital and focusing the UK portfolio on London and the South East, it said. Following the completion of the transaction, CLS will hold only two assets in the UK outside of the South East. "We continue to see significant opportunities for acquisitions across our core markets, and this transaction will allow us to recycle capital to capitalise on those opportunities," explained Chief Executive Fredrik Widlund.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Redx Pharma, up 28%. The drug discovery and development company said it has been in discussions with Samuel Waksal, the founder of ImClone Systems and Kadmon Pharmaceuticals, about a possible cash takeover offer. Redx cautioned, however, there was as yet no "firm intention" to make an offer and there can be no certainty that the offer will be made. Waksal has until 1700 GMT on January 28 to make a firm offer, the company said. Redx also said it has been in discussions with shareholders and third-party healthcare specialist investors regarding longer-term funding of the company, in order to advance its medicines for cancer and fibrosis to the next stage trials. Therefore the company is asking shareholders for permission to agree to the capitalisation of a GBP2.5 million loan into ordinary shares at 5.25 pence per share. Back in June, the company had signed a loan agreement with Moulton Goodies - which has 18% stake in Redx - for a fixed-rate secured loan note facility of up to GBP2.5 million.

----------

Lansdowne Oil & Gas, up 18%. The exploration company said it has further extended the repayment date of its outstanding GBP1.0 million loan with LC Capital Master Fund, which had been due on Tuesday, to June 30 next year. The move follows a previous half-year extension, reported on June 28. Also at that time, the AIM-listed company had secured debt funding of GBP150,000 from LC Capital and GBP150,000 from Brandon Hill Capital by way of loan note. Lansdowne said that debt facility was expected to provide sufficient funds to carry the company through to the end of 2019. The company did not provide any further update regarding its cash position.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Bango, down 9.2%. The mobile commerce company reported continued growth in end-user spend, which is expected to achieve GBP1.1 billion in 2019, resulting in revenue growth for the year of 40% to "at least" GBP9.3 million. Adjusted earnings before interest, taxes, depreciation, and amortization for the full year is positive and in excess of GBP400,000. The year before, the company recorded an adjusted Ebitda loss of GBP870,000. However, this strong results will be still below market forecasts primarily due to a Customer Data Platform license and Marketplace supply deal not concluding in December as expected. These deals are now expected to close in early 2020, Bango said. The company said operating costs remain stable and in line with expectations. Bango said it continues to invest in research & development, growing the data monetisation business and boosting the Bango platform.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

More News
11 Mar 2020 10:23

Redx Pharma Optimistic As Loss Narrows And Cancer Trial Progresses

Redx Pharma Optimistic As Loss Narrows And Cancer Trial Progresses

Read more
28 Feb 2020 18:47

UPDATE: Redx Pharma To Get GBP26 Million Injection Amid No Yesod Bid

UPDATE: Redx Pharma To Get GBP26 Million Injection Amid No Yesod Bid

Read more
28 Feb 2020 18:08

No Redx Pharma Takeover As Yesod Opts Not To Make Offer

No Redx Pharma Takeover As Yesod Opts Not To Make Offer

Read more
14 Feb 2020 17:11

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

Read more
28 Jan 2020 14:15

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

UK Regulator Extends Deadline For Possible Redx Pharma Cash Offer

Read more
24 Jan 2020 11:51

Moulton Goodies Raises Stake In Redx Pharma To 42% From 18%

Moulton Goodies Raises Stake In Redx Pharma To 42% From 18%

Read more
9 Jan 2020 16:02

Redx Pharma nominates next drug development candidate

(Sharecast News) - Drug discovery and development company Redx Pharma announced the nomination of RXC007 as its next drug development candidate for the treatment of fibrosis on Thursday.

Read more
9 Jan 2020 11:17

Redx Pharma Nominates Another Anti-Fibrosis Drug Candidate

Redx Pharma Nominates Another Anti-Fibrosis Drug Candidate

Read more
31 Dec 2019 09:12

Redx Pharma Shares Soar On Discussions Over Possible Takeover Offer

Redx Pharma Shares Soar On Discussions Over Possible Takeover Offer

Read more
31 Dec 2019 08:51

LONDON MARKET OPEN: Stocks Start Mostly Lower Amid Profit Taking

LONDON MARKET OPEN: Stocks Start Mostly Lower Amid Profit Taking

Read more
19 Nov 2019 12:29

Redx collaboration with MDC awarded Innovate UK funding

(Sharecast News) - Redx Pharma announced on Tuesday that Innovate UK has awarded biomedical catalyst funding to Redx and Medicines Discovery Catapult (MCD).

Read more
19 Nov 2019 11:53

Redx Pharma Secures Funding To Develop Lung Condition Therapies

Redx Pharma Secures Funding To Develop Lung Condition Therapies

Read more
19 Aug 2019 10:22

Redx Pharma Gets Approval To Escalate Dose In RXC004 Study

(Alliance News) - Redx Pharma PLC on Monday said it has successfully completed dosing of the first cohort of patients in its ongoing phase 1/2 study with RXC004.RXC004 is an oral porcupine

Read more
19 Aug 2019 09:43

Redx Pharma gets green light to escalate dose in RXC004 study

(Sharecast News) - Drug discovery and development company Redx Pharma has successfully completed dosing of the first cohort of patients in its ongoing phase 1 and 2 study with 'RXC004', it announced on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.